Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume – Still a Buy?

Posted by John Perry on Apr 14th, 2026

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) saw strong trading volume on Tuesday . 81,708 shares changed hands during trading, a decline of 17% from the previous session’s volume of 98,114 shares.The stock last traded at $10.48 and had previously closed at $10.62.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

Get Our Latest Stock Analysis on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The stock has a market cap of $17.85 billion, a P/E ratio of 13.80, a PEG ratio of 0.82 and a beta of 0.19. The business has a 50 day moving average price of $11.07 and a 200 day moving average price of $9.55. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its earnings results on Friday, January 30th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.09. The business had revenue of $966.53 million for the quarter, compared to the consensus estimate of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. As a group, sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.